Enhanced immune responses to an adenovirus CEA vaccine in CD4 +CD25+ regulatory T-cell inactivated mice

Expert Review of Vaccines

Volumn 6, Issue 1, 2007, Pages 21-23

  Pietersz, Geoffrey A ^a  

^a BURNET INSTITUTE   (Australia)

Author keywords

Adenovirus; Anti CD25; Carcinoembryonic antigen; Gene therapy; Regulatory T cell; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE DEPLETION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR IMMUNITY; VACCINATION;

EID: 33846895485     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.1.21     Document Type: Article

References (16)

1. +) regulatory T-cell inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther. DOI: 10.1038/sj.cgt.7701004 (2006) (Epub ahead of print).
2. + regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol. 13(9), 1252-1258 (2006).
3. + regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 13(10), 613-620 (2004).
4. reg) and increasing tumor immunity can lead to autoimmunity. This must be kept in mind when conducting clinical trials.
5. Facciabene A, Aurisicchio L, Elia L et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum. Gene Ther. 17(1), 81-92 (2006).
6. Mennuni C, Calvaruso F, Facciabene A et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117(3), 444-455 (2005).
7. reg may give depletion or inactivation.
8. + T regulatory cells. J. Immunol. 176(6), 3301-3305 (2006).
9. + T regulatory cells". J. Immunol. 177(4), 2036; author reply 2037-2038 (2006).
10. + T regulatory cells". J. Immunol. 177(4), 2036-2037; author reply 2037-2038 (2006).
11. reg in human cancer.
12. Motoyoshi Y, Kaminoda K, Saitoh O et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Reports 16(1), 141-146 (2006).
13. Li B, Lalani AS, Harding TC et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12(22), 6808-6816 (2006).
14. Knutson KL, Dang Y, Lu H et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177(1), 84-91 (2006).
15. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005).
16. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003).